Avsola (infliximab-axxq) is a biosimilar to Remicade, a widely-prescribed monoclonal antibody that helps the body’s immune system by targeting and destroying certain cells helping to protect healthy cells from damage. Specifically it is a tumor necrosis factor (TNF) blocker used for many chronic inflammatory conditions. Avsola was approved by the FDA in December, 2019 as a biosimilar to Remicade.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
Biologics (TNF blockers)
WHAT IT TREATS:
Three times in the first six weeks, then every 8 weeks
Length of infusion:
About two hours
FOR MORE INFORMATION: